© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Escitalopram Oxalate is a fine pharmaceutical raw material found in the world of active pharmaceutical ingredients. It forms the foundation for the preparation of antidepressant medications and finds wide use in mental health treatment. With countless people searching for safe and effective therapies, understanding the specifics of this substance matters not just for chemists but for anyone tracking the progress of modern healthcare. Escitalopram Oxalate appears as a solid, crystalline powder, and its physical presence reveals much about its handling, storage, and eventually, its application in a tablet or solution.
On close inspection, pure Escitalopram Oxalate presents as a white to off-white powder or as gleaming flakes, showing a clean texture with minimal moisture. Chemists know that the substance has a molecular formula of C20H21FN2O•C2H2O4 and a molecular weight of about 414.43 g/mol. Its crystallinity influences the way the compound dissolves during synthesis, affecting the overall process from raw material to finished drug. The density is specific, ranging from 1.2 to 1.5 g/cm³, placing it in the moderate range for organic compounds of similar class. Changes in structure or texture, either in pearls, solid chunks, or as a solution, offer clues about the stability and purity of each batch.
Each shipment of Escitalopram Oxalate comes with rigorous specification sheets. Chemists cross-check purity levels, identification assays, melting point readings—usually hovering just below 200°C—moisture content, and particle size. Those factors drive suitability for conversion into finished dose forms. The global movement of pharmaceutical ingredients owes much to standardized systems, and here the Harmonized System (HS) Code—2933399090—stands as the identifier most often linked to Escitalopram Oxalate shipments. Now suppliers, customs, and buyers can all speak a common language when describing, trading, or regulating the powder.
At its core, Escitalopram Oxalate stands out as an oxalate salt version of escitalopram, boosting both shelf stability and water solubility. Those tweaks separate it from freebase forms, making it both easier to manufacture and more consistent in pharmaceutical preparations. In typical lab settings, scientists appreciate how the molecule’s structure—anchored by halogen and amine groups—delivers the required selectivity in treating mental health disorders. Structural diagrams show a carefully constructed balance of rings and linkages, giving each dose both the desired effect and a footprint for further modification.
Escitalopram Oxalate takes on several appearances, each revealing something about its journey from raw material to finished product. As a pure solid or crystal, it offers a hallmark of high purity, crucial when preparing reference standards or formulations with tight control ranges. Powder and flakes tend to be favored for batch dosing, dissolving well in various pharmaceutical solvents and allowing ease of measurement. Laboratory staff might find the substance available in bead or pearlized forms, reducing dust and static, helpful in high-throughput manufacturing. In rare settings, processed Escitalopram Oxalate appears blended in solutions for fast dosing, quality control, or analytical testing prior to further use.
As with all active pharmaceutical ingredients, there’s a need for respect in handling. Escitalopram Oxalate carries a profile that deserves proper safety precautions, even before entering a finished medicinal product. Contact, inhalation, or ingestion outside of intended pharmaceutical use brings risk of adverse health reactions, so gloves and masks become part of the daily routine in most facilities. Storage away from moisture, direct sunlight, and heat helps maintain chemical stability, further protecting handlers. Official documentation—such as Safety Data Sheets (SDS)—routinely cite moderate toxicity levels, reinforcing the need for locked cages, specialized waste disposal, and clearly marked hazardous-material labeling on containers.
The journey of Escitalopram Oxalate to the end user begins with a global network of chemical manufacturers. Purity, traceability, and regulatory compliance mark every shipment, documented by batch numbers, certificates of analysis, and transportation forms. Only reliable manufacturers with solid quality controls can be trusted to supply this raw material, given its ultimate medical use. Supply chain disruptions, whether due to geopolitical instability or logistics breakdown, directly touch the ability of pharmacies and hospitals to steward mental health therapies. For stakeholders, the value of stable supplies, fair pricing, and guaranteed origins grows with every batch sourced and every vouchsafe certificate produced.
Given the critical place Escitalopram Oxalate holds in medicine, any weaknesses in production or distribution trigger real-world consequences. Shortages result from fluctuating demand, shifting regulations, or raw material scarcity. Diversifying sources, enforcing independent quality audits, and building up local manufacturing capacity shortens wait times and lowers risk. Regular updates of safety protocols—based on new toxicological data or improved chemical handling technology—cut down on exposure risks for workers and end users. By pairing rigorous specification checks with active feedback from frontline staff, manufacturers can better spot inconsistencies or improvements before mistakes reach human hands.
